Lost in translation: Differences in antimicrobial indication approval policies between the United States and Europe

Clinical Therapeutics

Volumn 31, Issue 7, 2009, Pages 1595-1603

  Pappas, Georgios ^a,b   Ierodiakonou, Vrettos ^b   Falagas, Matthew E ^b,c,d  

^a Institute of Continuing Medical Education of Ioannina   (Greece)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antimicrobials; indications; licensing; regulatory bodies

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; LINEZOLID; MICAFUNGIN; POSACONAZOLE; RETAPAMULIN; TELITHROMYCIN; TIGECYCLINE; VORICONAZOLE;

ACUTE SINUSITIS; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; CANDIDEMIA; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG APPROVAL; ENDOCARDITIS; ENTEROCOCCAL INFECTION; EUROPE; HOSPITAL INFECTION; HUMAN; IMPETIGO; INVASIVE CANDIDIASIS; MENINGITIS; OROPHARYNX CANDIDIASIS; OSTEOMYELITIS; PHARYNGITIS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; TREATMENT INDICATION; UNITED STATES; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-INFECTIVE AGENTS; DRUG APPROVAL; EUROPEAN UNION; HUMANS; INFECTION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 68649094491     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.06.016     Document Type: Article

References (24)

1. US Food and Drug Administration. What we do. http://www.fda.gov/AboutFDA/WhatWeDo/default.htm Accessed June 17, 2009
2. US Food and Drug Administration. Legislation. http://www.fda.gov/RegulatoryInformation/Legislation/default.htm Accessed June 17, 2009
3. European Medicines Agency (EMEA). About EMEA-structure. http://www.emea.europa.eu/htms/aboutus/emeaoverview.htm Accessed February 9, 2009
4. European Directorate for the Quality of Medicines & HealthCare. About the EDQM, its vision & mission. http://www.edqm.eu/en/About-the-EDQM-amp-its-Missions-604.html Accessed June 17, 2009
5. Spellberg B., Guidos R., Gilbert D., et al., the Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 46 (2008) 155-164
6. Trials and tribulations of antibiotic development. Lancet Infect Dis. 8 (2008) 209
7. Tillotson G. Pneumonia workshop raises more questions than answers. Lancet Infect Dis. 8 (2008) 221
8. Cohen M.L. Changing patterns of infectious disease. Nature. 406 (2000) 762-767
9. Psaty B.M., and Furberg C.D. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 357 (2007) 67-69
10. US Food and Drug Administration (FDA). Drug information. http://www.fda.gov/cder/drug/default.htm Accessed February 9, 2009
11. Toivonen M. How bacteraemia is reviewed by medicines licensing authorities in Europe. Int J Antimicrob Agents. 30 Suppl 1 (2007) S103-S107
12. Sobolski G.K., Barton J.H., and Emanuel E.J. Technology licensing: Lessons from the US experience. JAMA. 294 (2005) 3137-3140
13. Nieminen O., Kurki P., and Nordström K. Differences in product information of biopharmaceuticals in the EU and the USA: Implications for product development. Eur J Pharm Biopharm. 60 (2005) 319-326
14. Redmond K. The US and European regulatory systems: A comparison. J Ambul Care Manage. 27 (2004) 105-114
15. US FDA's non-inferiority stance could slow sinusitis approvals. SCRIP World Pharmaceutical News (Sept 18, 2006) 27
16. Chang F.Y., Peacock Jr. J.E., Musher D.M., et al. Staphylococcus aureus bacteremia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 82 (2005) 333-339
17. Johnson L.B., Almoujahed M.O., Ilg K., et al. Staphylococcus aureus bacte-remia: Compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis. 35 (2003) 782-789
18. International Conference on Harmonisation (ICH). http://www.ich.org Accessed June 15, 2009
19. European Medicines Agency (EMEA). Closer ties on medicines safety between European and Canadian regulatory authorities. http://www.emea.europa.eu/pdfs/general/direct/pr/EU-Canada_confidentiality.pdf Accessed February 9, 2009
20. European Medicines Agency (EMEA). Public Statement: EU (European Commission and EMEA) and FDA agree on guiding principles for joint FDA EMEA voluntary genomic data submission briefing meetings. http://www.emea.europa.eu/pdfs/general/direct/pr/19136706en.pdf Accessed February 9, 2009
21. US Department of Health and Human Services, Food and Drug Administration. Common EMEA/FDA application for orphan medicinal product designation. http://www.fda.gov/oia/FDA-3671.pdf Accessed February 9, 2009
22. US Food and Drug Administration (FDA). FDA, European Medicines Agency to consider additional test results when assessing new drug safety. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01850.html Accessed February 9, 2009
23. European Medicines Agency (EMEA). Confidentiality arrangements concluded between the EU (EC and EMEA) and the US FDA/DHHS. http://www.emea.europa.eu/pdfs/general/direct/pr/confidentiality.pdf Accessed February 9, 2009
24. Sutter S. Unified FDA/EMEA medicine reviews not in the cards. 2008. Scrip Editors' Blog. http://feeds2.feedburner.com/ScripEditorsBlog Accessed June 18, 2009